Knee osteoarthritis is the most prevalent joint disease in the Netherlands with 693,400 patients in 2018. The prevalence of this disease is still rising, most rapidly among patients of working age in a low socioeconomic position. The rising pension age will further increase the number of workers with knee osteoarthritis. This will drive up the societal costs, which are found to be 148 Euro for medical costs and 723 Euro for productivity loss per working Dutch knee osteoarthritis patient per month.
The ultimate treatment option is knee prosthesis surgery. By 2030 the annual number of surgeries will be nearly doubled to 57,900 compared to the 29,790 in 2018. In 2030 more than half of the patients are of working age. Unfortunately, return to work after knee prosthesis surgery is unfavorable: 3 out of 10 workers no longer start working after surgery. Furthermore, of those who do return to work, more than 70% have a great deal of difficulty performing knee demanding activities such as kneeling.
Given the exponential growth in the number of workers with knee osteoarthritis and the impact the disease has on society and patients, we developed the ACTIVE trial. In this multicenter trial we evaluate the (cost-)effectiveness of Goal Attainment Scaling and the personalized m/e-health intervention IkHerstel that provides knee arthroplasty patients with tailored recovery advice, and compare this intervention with care as usual for return to daily life activities including work and sport.
We are only able to perform the ACTIVE trial thanks to the following clinics and hospitals:
- Amphia ziekenhuis, Breda
- St. Anna, Geldrop
- Onze Lieve Vrouwe Gasthuis, Amsterdam
- Maastricht UMC, Maastricht
- Alrijne ziekenhuis, Leiderdorp
- Flevoziekenhuis, Almere
- Kliniek ViaSana, Mill
- Ziekenhuis Gelderse Vallei, Ede
- Bergman Kliniek, Naarden
- Maxima Medisch Centrum
- Catharina Ziekenhuis, Eindhoven
Contact: Carlien Straat: c.straat@amsterdamumc.nl
